TAGRISSO (osimertinib) Patient Assistance Program
Don’t let lung cancer treatment costs derail your fight. We help eligible patients access Tagrisso (osimertinib) for as little as $69.95 per month through manufacturer Patient Assistance Programs.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Tagrisso Is The Preferred First-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer — The Most Advanced Oral EGFR Inhibitor Available
- Retail Cost Is Approximately $17,746 Per Month Without Insurance, Totaling Over $212,000 Per Year
- AffordMyPrescriptions Provides Access To Tagrisso For Just $69.95/Month Through The Patient Assistance Program
- No Generic Version Of Osimertinib Is Currently Available In The United States
What is Tagrisso Prescription Assistance Program?
The Tagrisso Prescription Assistance Program is a manufacturer-sponsored initiative that provides Tagrisso at no medication cost to qualifying patients who cannot afford it. The program is accessible through the manufacturer’s patient support services. Financial assistance is available for commercially insured patients, uninsured patients, and those who have been denied insurance coverage. Eligibility is determined on a case-by-case basis.
A lung cancer diagnosis changes everything in an instant — and when genetic testing reveals that your tumor carries an EGFR mutation, your oncologist may tell you that a targeted therapy exists that can control your cancer far more effectively than chemotherapy. Tagrisso represents the most advanced version of this targeted approach, and for many patients, it is the difference between aggressive disease progression and years of controlled cancer
AffordMyPrescriptions ensures that your tumor’s genetic profile, not your financial status, determines your treatment. For a flat $69.95 per month, our Patient Advocates manage every step of your enrollment.
Pharmacy Price Comparison
- Without assistance, Tagrisso costs significantly more at retail pharmacies than through our advocacy service. Discount programs offer some relief, but they don't come close to what a Patient Assistance Program provides, if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$17,750.00 | Save ~$17,680/mo |
| CVS Specialty | ~$17,800.00 | Save ~$17,730/mo |
| Walmart | ~$17,700.00 | Save ~$17,630/mo |
| Costco | ~$17,720.00 | Save ~$17,650/mo |
| List Price | ~$17,746.00 | Save ~$17,676/mo |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. Afford My Prescriptions Advocacy Service bypasses retail pricing by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Tagrisso Prescription Program?
When you’re battling lung cancer and your oncologist prescribes Tagrisso because genetic testing confirmed your tumor’s EGFR mutation, the administrative complexity of accessing a $17,746-per-month specialty medication should not add to your burden. Insurance prior authorizations, specialty pharmacy coordination, copay assistance enrollment, and annual re-enrollment all demand time and energy during the most challenging period of your life.
Our trained Patient Advocates specialize in oncology medication access and manage every administrative detail on your behalf. From the moment you enroll, your advocate prepares your application, coordinates with your oncologist to gather required medical documentation (including EGFR mutation test results), submits everything to the appropriate program, and tracks your status through every stage. When your medication is due for refill, they coordinate with your specialty pharmacy proactively.
Our pricing is simple and predictable: $69.95 per month — every month. While the medication itself is provided at no cost through the manufacturer’s program, our monthly fee covers all advocacy, application management, oncologist coordination, and specialty pharmacy oversight. If we’re unable to secure access, you won’t be charged.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through Afford My Prescriptions is the better long-term solution:
Limitations of Coupons
- Specialty pharmacy network limits coupon applicability
$0 copay program excludes Medicare/Medicaid/government insurance
- Even with copay program, $26,000 annual savings cap applies
Insurance prior authorization typically required
- Cards expire and require constant renewal
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly from the manufacture
- We manage all paperwork, specialty pharmacy logistics, and renewals
Medicare Part D patients accepted
DO YOU QUALIFY?
Eligibility is generally determined by annual household income levels. Most programs follow guidelines that include a limit of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. A confirmed EGFR mutation is required.
- You are a U.S. citizen or legal resident
- You Have A Valid Tagrisso Prescription From A Licensed U.S. Oncologist
- You Have A Confirmed EGFR Mutation Detected By Appropriate Testing
- You Are Uninsured, Underinsured, Or Have Been Denied Insurance Coverage
- Medicare Part D Patients Accepted
Understanding Tagrisso:
Tagrisso (osimertinib) is a once-daily prescription oral tablet used to treat adults with non-small cell lung cancer (NSCLC) that has specific epidermal growth factor receptor (EGFR) mutations. It is a third-generation EGFR inhibitor approved for multiple treatment settings: as adjuvant therapy after surgical removal of early-stage EGFR-mutated tumors, as first-line treatment for metastatic EGFR-mutated NSCLC, and as treatment after progression on earlier EGFR-targeted therapies. Available in 40 mg and 80 mg tablets.
How It Works:
Tagrisso is a third-generation inhibitor that targets EGFR gene mutations that cause cancer cells to multiply uncontrollably. It is specifically engineered to block both original mutations and the T790M resistance mutation that often defeats older drugs. By binding irreversibly to these proteins, it shuts down growth signals and can effectively cross the blood-brain barrier to treat cancer that has spread to the brain.
Form and Use:
This medication is available in 40 mg and 80 mg tablets, with the standard adult dose being 80 mg taken once daily. It can be taken with or without food at the same time each day and is typically dispensed through specialty pharmacies. Patients continue the treatment for as long as their oncologist determines the medication is providing a clinical benefit.
Generic Availability:
As of April 2026, there is no FDA-approved generic version of Tagrisso (osimertinib) available in the United States due to patent protection. While older generic inhibitors like erlotinib are cheaper, they are less effective and do not target the T790M mutation. Patients can access the drug for $69.95 per month through the AffordMyPrescriptions assistance program to avoid the high retail cost of approximately $17,746.
Warnings:
Tagrisso can cause serious side effects such as interstitial lung disease, heart rhythm issues (QTc prolongation), cardiomyopathy, and keratitis. It is essential to inform your healthcare provider of all medical conditions before starting treatment. Patients must not stop taking the medication without strict medical supervision.
FAQ (Frequently Asked Questions)
How Much Does Tagrisso Cost Without Insurance?
Tagrisso costs approximately $17,746 per month ($212,000+ per year). The manufacturer offers a $0 copay program for commercially insured patients (up to $26,000/year savings). Most Medicare and insurance plans cover Tagrisso, though prior authorization is typically required. Through AffordMyPrescriptions, qualifying patients receive Tagrisso at no medication cost — our $69.95 monthly fee covers advocacy and program management
Is This The Same Tagrisso I'd Get At A Pharmacy?
Yes. The Tagrisso supplied through the Patient Assistance Program is the same FDA-approved osimertinib medication dispensed at specialty pharmacies, supplied directly from the manufacturer.
Is There A Generic Version Of Tagrisso?
No. Tagrisso remains patent-protected and no FDA-approved generic is currently available. Older EGFR inhibitors like generic erlotinib are available but considered less effective as first-line therapy.
Can I Get Tagrisso Through The PAP If I Have Medicare?
Yes. Medicare patients may qualify for the Patient Assistance Program. As of 2026, Medicare Part D plans also have a $2,100 annual out-of-pocket cap. Our advocates can help you evaluate the best pathway.
How Is Tagrisso Different From Tarceva (Erlotinib)?
Both target EGFR mutations in lung cancer, but they are different generations. Tagrisso is a third-generation EGFR inhibitor that blocks both original EGFR mutations and the T790M resistance mutation. Tagrisso also crosses the blood-brain barrier more effectively. Current guidelines recommend Tagrisso as the preferred first-line treatment.
What if my application is denied?
Our Patient Advocates will immediately explore every alternative — including the manufacturer’s $0 copay savings program, PAN Foundation and other co-pay assistance foundations, Medicare Extra Help, insurance prior authorization appeals with EGFR mutation documentation, generic erlotinib as a lower-cost alternative ($92–$223/month), and clinical trial enrollment for newer targeted therapies.
Take Control of Your Medication Costs
If you are struggling with the high cost of Tagrisso, our team may be able to help you access assistance programs designed to make medications more affordable. Check your eligibility today and take the first step toward reducing your prescription costs.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.